New York Magazine examines cancer drug pricing

Share this article:
New York Magazine examines cancer drug pricing
New York Magazine examines cancer drug pricing

In a story published online on October 20th, New York magazine took readers through the Memorial Sloan-Kettering/Zaltrap pricing battle with Leonard Saltz, one of the three oncologists who penned the op-ed in the New York Times which started it all and concluded with Sanofi/Regeneron slashing the price of then new breast cancer drug Zaltrap in half due to "market resistance."

The seven-page article online also quoted Hagop Kantarjian, head of the Department of Leukemia at the University of Texas's MD Anderson Cancer Center, who is currently campaigning against Gleevec, a leukemia treatment whose price has tripled since 2001.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.